The VA psilocybin trial announced on August 5, 2026 is called PIVOT — Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression — and it is a Phase 3, multi-site randomized controlled trial with an estimated enrollment of 240 veterans. It is a genuinely significant step by a federal agency toward a Schedule I substance. It is also, as of this writing, a study in which nobody has been dosed.
Both of those things matter, so let us take them in order.
What the VA psilocybin trial is actually testing
Per the ClinicalTrials.gov registration, NCT07226232, PIVOT is quadruple-masked with parallel assignment, sponsored by the VA Office of Research and Development under org study ID MHBC-002-25S. Five sites are listed: the Birmingham VA Medical Center and Tuscaloosa VA Medical Center in Alabama, VA Portland Health Care System in Oregon, the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, and VA Puget Sound in Seattle. The principal investigator is Dr. Lori Lynne Davis in Birmingham.
Design: two dosing sessions. The first is randomized between two blinded psilocybin doses; one month later, every participant receives 25mg. The primary outcome is the Montgomery-Åsberg Depression Rating Scale at two weeks, with follow-up running six months. Eligibility runs ages 18 to 75 and requires failure of at least two prior antidepressant treatments plus a baseline MADRS of 20 or higher. Estimated primary completion is December 2, 2030.
VA Secretary Doug Collins framed it this way in the agency’s announcement: “Far too many Veterans are living with mental health conditions that don’t respond to available treatments. Under President Trump, VA is pursuing all avenues to evaluate new treatments and offer meaningful relief for those who have worn the uniform.”
The agency says the work will be done “in a safe, controlled, clinical setting using pharmaceutical-grade drugs under careful quality controls, stringent safety protocols that were developed with FDA, and in a setting that includes psychological support.” VA reports 20 active psychedelic clinical trials. The policy backdrop is an April 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness.
Three things to get right before you repeat this
One: “launches” does not mean anyone has been dosed. ClinicalTrials.gov still listed the overall status as NOT_YET_RECRUITING as of its August 7, 2026 version, with an estimated start date of July 30. The honest verb is “announced.”
Two: this is a depression trial, not a PTSD trial. The indication is treatment-resistant major depressive disorder. PTSD is a permitted comorbidity — “with or without,” in the registry’s language — and PTSD instruments are secondary outcomes. The primary endpoint is a depression scale. A lot of coverage is going to say “VA studying psilocybin for PTSD.” That is not what the protocol says.
Three: there is no placebo arm. The control is labeled an active comparator — a lower psilocybin dose — and at the one-month session everyone receives 25mg. Saying “psilocybin versus placebo” misdescribes the design.
One caution on naming: the registry lists the drug’s other name as COMP360, but the VA press release names no manufacturer. Do not attach a company to this without checking.
The pattern worth noticing
Results are years out, and VA is explicit that this changes nothing about access: “Clinical use of these therapies outside of research will only be considered by VA once FDA approval is granted.”
Which lands us in the same place we ended up last week on ibogaine. The federal government will fund rigorous research into a Schedule I compound for the people it sent to war — and will still test them for Schedule I compounds and act on the result. Congress will pay for the study and keep the policy that punishes the substance. That contradiction is not hypocrisy exactly; it is what happens when research policy and personnel policy live in different buildings and never talk. But veterans are the ones standing in the gap between them.
For related coverage see the CDC’s cannabis hyperemesis report and the military marijuana ban after rescheduling.
Watch the full episode
We break this down on Cannabis Legalization News with Thomas Howard and Miggy 420.
Watch the full episode on YouTube.
